Hi David,

I agree that Séralini has received more attention than he deserves and we should not contribute to this any further. If we had an idea about when we can expect Séralini’s paper to disappear from the archives, we may decide to not even mention his name at all.

In any case, even if this means that I have worked through Séralini’s “data” in vain, I also think we should remove any detailed discussion of this junk science from our MS.

We should rather include the Polish paper on the chronic rat study and potentially other publications fulfilling minimum validity criteria like number of rats per dose.

Best regards,

Redacted

Von: SALTIMIRAS, DAVID A [Redacted]
Gesendet: 18 March 2013 18:56
An: Redacted
Cc: Redacted
Betreff: RE: Glyphosate carc review v6
Wichtigkeit: Hoch

All,

Firstly, I agree with [Redacted] regarding order of studies reviewed. For the mouse studies, this will simply mean reversing order of the last two studies. More juggling of the order of the rat studies will be needed, so we will need to review changes carefully to ensure tables and text citations are correctly modified.
I agree with the bulk of [redacted] comments/changes, but would like to reconsider whether or not to include the detail on NHL in the epidemiology section – I believe it is important to dispel the myth of NHL as a single disease, especially for a future IARC weight of evidence review.

I also like Chris’s proposed rewritten section on exposure in the discussion; for clarity, I would like an example of a general public dietary exposure calculation.

**Update on Seralini publication** - A highly credible source informs me that the journal/publisher has asked Seralini to retract his paper from *Food and Chemical Toxicology*. I do not believe Seralini will voluntarily retract. However, there may now be sufficient grounds for the publisher to step in and remove/expunge the paper from their journal. Therefore, if we publish a review on the Seralini paper, we may further immortalize this poorly conducted research. I propose we cut Seralini from our review of industry sponsored chronic studies.

Furthermore, in five years time or so the Seralini paper may no longer be known of, but if published alongside our incredible regulatory data set, the Seralini research will always be revisited whenever someone cites our paper. If the Seralini paper is removed from the literature by the publisher, it should not be eligible for consideration if an IARC review of glyphosate takes place in the future. However, even if Seralini’s paper is retracted in the future, if we publish our review of his research we open the gate for its consideration in an IARC glyphosate review.

Based on the sponsor’s (Glyphosate Task Force) rationale for this paper, preparing for an IARC review to allow consideration of our regulatory data base (IARC will not consider unpublished studies) should such a review take place, I do not think we should include the Seralini paper. Given the extensive EFSA review and their outsourced reviews to MS experts in the attached, we simply do not have enough space to publish the justifiable criticisms of the Seralini paper.

Please let me know your thoughts. If you do not agree with cutting the Seralini paper, please explain your rationale and I will add this to the agenda for discussion at the GTF Toxicology Technical Working Group meeting on Friday this week.

Thank you all,

David Saltmiras, Ph.D., D.A.B.T.
Toxicology Manager
Regulatory Product Safety Center
Monsanto

Redacted

---Original Message---
From: Redacted
Sent: Monday, March 18, 2013 7:59 AM
To: Redacted
Cc: SALTMIRAS, DAVID A Redacted
Subject: RE: Glyphosate carc review v6

Redacted

For sure - I guess we will not do mayor changes to the message itself or the presentation of the individual study summaries (which the companies have to agree to), but we can still do editorial changes/different presentations of the same message and work on the fine tuning of the introduction and discussion. I just fear that the companies may take up to 6 weeks for review until all are in, and this may hold us up if we don't get it initiated.

Best regards,

Redacted

Redacted

Corporate Toxicologist | MA Europe

Feinchemie Schwebda GmbH

Direct mailing address:

Wieser Dorfstr. 23

79692 Kleines Wiesental

Germany
-----Original Message-----

From: Redacted
Sent: 18 March 2013 13:50
To: Redacted
Cc: SALTMIRAS, DAVID A (Redacted)
Subject: RE: Glyphosate carc review v6

ok, I agree if we still have the possibility of editorial changes.

Redacted

Am 2013-03-18 13:36 Redacted

> Dear colleagues,
>
> Here my latest comments (I used the version edited by David to make it
> a bit easier to implement without having too many versions to
> compare).
>
> I believe we are there - I propose that the last round of comments
> gets implemented and we circulate to the member companies for approval
right away, not to lose time on this end. In case we want to do some
polish meanwhile before submission, that should not have to go through
company review again.

Best regards,

Redacted

Europe

Feinchemie Schwebda GmbH

Direct mailing address:

Wieser Dorfstr. 23

79692 Kleines Wiesental

Germany

Redacted

Redacted

www.ma-industries.com

-----Original Message-----

From: SALTMIROS, DAVID A (AG/1000)

Redacted
To: Redacted

Subject: RE: Glyphosate carc review v6

All,

Thank you for the perseverance you have shown in reviewing multiple revisions of this important paper. I have thoroughly reviewed and have minor comments/suggestions, except for the added section on the Seralini paper, to which I have rearranged and consolidated to relevant data/discussion to carcinogenicity.

I believe we are very close to having a final draft for company internal reviews. Please comment pack to Volker, especially on the Seralini section in the attached. If Volker would please try to address this ASAP, we may complete this before the anticipated BVL preliminary draft reevaluation assessment report.

Regards,

David Saltmiras, Ph.D., D.A.B.T.
Toxicology Manager
Regulatory Product Safety Center
Monsanto
ph Redacted


> -----Original Message-----
> From: Redacted
> Sent: Thursday, March 14, 2013 11:26 AM
> To: Redacted SALTMIRAS, DAVID A Redacted
> Subject: Glyphosate carc review v6
>
> Gentlemen,
>
> attached you find the newest draft of the glyphosate cancer review.
>
> I have struggled hard, but I have summarised and discussed the
> Sérinali paper. This was suggested by Redacted and I agree with him
> that we cannot simply say "this is junk science" and not mention it
> further. Seralini touches on carcinogenicity of glyphosate-based
> herbicides so we probably cannot ignore it. I know that Christian was
> strongly in favour of "less Sérinali", but I guess the coverage is
> necessary to expose the subterranean quality of this study by
> "rounding it up" against the GLP studies.
>
> I have now created a separate MAK-style table for all studies.
> Publishers normally ask for the number of tables to be kept at a
> minimum and have thus deleted the summary tables listing all the
> studies and the tables with specific findings made in individual
> studies. We now have 16 tables in the MS and a total of 27 pages
> excluding Title page, References and Tables.
As always, your comments are welcome!

Kind regards,

Redacted

-----Ursprüngliche Nachricht-----

Redacted

Gesendet: 04 March 2013 07:41

An: Redacted; SALTMIRAS, DAVID A (AG/1000)
Cc: Redacted

Betreff: RE: Glyphosate carc review v5

Dear colleagues,

Here my comments as well.

Best regards,

Redacted

Europe

Feinchemie Schwebda GmbH
Direct mailing address:
Wieser Dorfstr. 23
79692 Kleines Wiesental
Germany
Direct Line: Redacted
Redacted
www.ma-industries.com

-----Original Message-----
From: Redacted
Sent: 02 March 2013 21:13
To: SALTMIRAS, DAVID A Redacted
Cc: Redacted
Subject: RE: Glyphosate carc review v5

Dear all,

please find some comments on the most recent draft.

Sincerely

Redacted

Comments to latest revision of the glyphosate draft
General:
The draft has been considerably improved, although it lacks essential
data for evaluation of the different long term studies.
> Table 2:
> The studies need to be identified (e.g. Monsanto 2010 or so) although
> these are chronic, not lifetime studies, the number of animals per
> group (under type of study) and the number of affected animals per
> group should be provided under Targets/Main effects.

> Table 3:
> The same applies to this Table: No of animals per group and the number
> of affected animals per group for the different effects described.
> Please always indicate the target organ, which e.g. is not given for
> study No 6.

> Delete Only in study 5 and 6.
> Study 9, please check under dose levels and LOAEL 814 versus 841.
> Tables 5, 6 etc. Whenever you provide details on studies listed in
> Table 3 please include the number used in Table 3 as well.
> Tables 6 etc. It is not clear what are the criteria for describing the
> different details given in these tables. Something like “The prominent
> effects in this studies are xyz. Further details are given in Table x.

> That's it in Kürze

> Best regards

> [Redacted]

>> [Redacted]
>>
>> I have thoroughly reviewed and commented in the latest revision of
the glyphosate carcinogenicity review manuscript, attached. More specifically, I refined the introduction and added citations; asked Larry Kier to review the genotoxicity paragraph and incorporated his suggestions in both this section and the conclusion; thought it important in the epidemiology section to address the very recent Alavanja et al. (2013) paper and his claim of a glyphosate association with non-Hodgkin's lymphoma. I think this is now thoroughly addressed in a reasonable manner, but please review and let me know your thoughts (paper attached); added some minor clarifying detail on two Monsanto studies; made a couple of comments to be addressed on non-Monsanto studies; provided an alternative to the risk assessment paragraphs in the discussion, with justification in the comments; added my declaration of interest; included minor points of clarification to tables; and asked for a couple clarifications on Table 14 (FSC mice data).
NOTE: I would like all the data owners to review their data tables 5-14 and confirm accuracy. Can you please forward the respective tables to the member company representatives to confirm their data? No need for the Monsanto Tables 5 and 12.

I also took the liberty to discuss the manuscript submission with Roger McClellan, Editor in Chief of Critical Reviews in Toxicology.
Roger requested that we provide 7-8 suggestions of peer reviewers, so please think about appropriate reviewers for this paper. Hopefully we can finalize this manuscript soon and share with the Glyphosate Task Force Toxicology Technical Working Group to start relevant company internal approvals before submitting to Critical Reviews in Toxicology.

David Saltmiras, Ph.D., D.A.B.T.
Toxicology Manager
Regulatory Product Safety Center
Monsanto

FROM:

SENT: Tuesday, February 26, 2013 8:03 AM

TO:
>> SUBJECT: Glyphosate care review v5

>>

>> Dear colleagues,

>>

>> I have worked through the various comments and suggestions from our
>> last telephone call. In addition, I have drafted a separate document
>> that summarises the studies in the MAK commission style (see
>> attachments).

>>

>> I hope that I implemented all of your suggestions. Let me know if you
>> are missing something.

>>

>> Kind regards,

>>

>> [Redacted]

>>

>> --

>>

>> [Redacted]

>>

>> European Registered Toxicologist (DGPT)

>>

>> Senior Expert Toxicology

>>

>> [Redacted]
Redacted

Redacted

Redacted

Redacted

Redacted

Sitz Dynamostr. 19, 68165 Mannheim, Germany

Amtsgericht Mannheim HRB 9339

Links:

Redacted

Feinchemie Schwebda GmbH

Edmund-Rumper-Str. 6
> 51149 Koeln
>
> >
> > Redacted
> >
> > Amtsgericht Koeln HRB 66957
> >
> > This email and any attachments are confidential, may be legally
> > privileged and protected by copyright. If you are not the intended
> > recipient, dissemination or copying of this email and any attachments
> > is prohibited. If you have received this in error, please notify the
> > sender by replying by email and then delete the email completely from
> > your system.
> >
> > Diese eMail-Nachricht und gegebenenfalls beigefuegte Anlagen koennen
> > vertrauliche Informationen enthalten. Sofern Sie nicht der
> > bestimmungsgemaesse Empfaenger sind, ist das Kopieren und/oder
> > weiterleiten dieser Nachricht untersagt. Sofern Sie diese Nachricht
> > irrtuemlich erhalten haben, bitten wir Sie, sich an den Absender zu
> > wenden indem Sie auf diese Nachricht antworten. Danach loeschen Sie
> > diese Nachricht bitte vollstaendig aus Ihrem System.
> >
> >
> > Feinchemie Schwebda GmbH
> >
> > Edmund-Rumper-Str. 6
> >
> > 51149 Koeln
> >
> > Redacted
This email and any attachments are confidential, may be legally privileged and protected by copyright. If you are not the intended recipient, dissemination or copying of this email and any attachments is prohibited. If you have received this in error, please notify the sender by replying by email and then delete the email completely from your system.


Feinchemie Schwebda GmbH

Edmund-Rumpler-Str. 6

51149 Koeln

Amtsgericht Koeln HRB 66957

Redacted
This email and any attachments are confidential, may be legally privileged and protected by copyright. If you are not the intended recipient, dissemination or copying of this email and any attachments is prohibited. If you have received this in error, please notify the sender by replying by email and then delete the email completely from your system.